Internet Archive Scholar

Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry

T. Simon, P. G. Steg, M. Gilard, D. Blanchard, L. Bonello, M. Hanssen, H. Lardoux, P. Coste, T. Lefevre, E. Drouet, G. Mulak, V. Bataille (+3 others)
2011 Circulation  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (811.4 kB)
https://web.archive.org/web/20180723041346/http://circ.ahajournals.org/content/circulationaha/123/5/474.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL. The file type is application/pdf.

Background-Clopidogrel requires metabolic activation by cytochrome P450 2C19 (CYP2C19). Proton pump inhibitors (PPIs) that inhibit CYP2C19 are commonly coadministered with clopidogrel to reduce the risk of gastrointestinal bleeding. This analysis compares treatment outcomes for patients in the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) who did or did not receive clopidogrel and/or PPIs. Methods and Results-The FAST-MI registry included 3670
more » ... s (2744 clopidogrel-and PPI-naı ¨ve patients) presenting with definite MI. Patients were categorized according to use of clopidogrel and/or PPI within 48 hours after hospital admission. PPI use was not associated with an increased risk for any of the main in-hospital events (in-hospital survival, reinfarction, stroke, bleeding, and transfusion). Likewise, PPI treatment was not an independent predictor of 1-year survival (hazard ratio, 0.97; 95% confidence interval [CI], 0.87 to 1.08; Pϭ0.57) or 1-year MI, stroke, or death (hazard ratio, 0.98; 95% CI, 0.90 to 1.08; Pϭ0.72). No differences were seen when the type of PPI or CYP2C19 genotype was taken into account. In the propensity-matched cohorts, the odds ratios for major in-hospital events in PPI versus no PPI were 0.29 (95% CI, 0.06 to 1.44) and 1.70 (95% CI, 0.10 to 30.3) for patients with 1 and 2 variant alleles, respectively. Similarly, the hazard ratio for 1-year events in hospital survivors was 0.68 (95% CI, 0.26 to 1.79) and 0.55 (95% CI, 0.06 to 5.30), respectively. Conclusion-PPI use was not associated with an increased risk of cardiovascular events or mortality in patients administered clopidogrel for recent MI, whatever the CYP2C19 genotype, although harm could not be formally excluded in patients with 2 loss-of-function alleles.
doi:10.1161/circulationaha.110.965640 pmid:21262992 fatcat:rrp6nfittfcmnjdriikznyh5me
Citation

T. Simon, P. G. Steg, M. Gilard, D. Blanchard, L. Bonello, M. Hanssen, H. Lardoux, P. Coste, T. Lefevre, E. Drouet, G. Mulak, V. Bataille, J. Ferrieres, C. Verstuyft, N. Danchin. "Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry." Circulation 123.5 (2011) 474-482